Summary
A 12-part survey was performed of 446 medical writing professionals in pharmaceutical companies in order to discover the major causes of delay in completing a regulatory submission, the most difficult steps in the process and the biggest hurdles for novice writers. Responses were received from 39 medical writers in 31 companies. Last-minute revisions and late-breaking study results were the main causes of delays. Managing a multi-country dossier was the most difficult step and maintaining consistency across disciplines and documents was the second. Novice writers had difficulty seeing the big picture of the whole submission and were unfamiliar with document structure and content.
Similar content being viewed by others
References
Purcell T. Using cross-functional teams to write combined clinical and statistical research reports: a communication specialist’s perspective. Drug Inf Jnl 1999; 33:159–163.
Higgins P, Hovde M. Innovative writing techniques for regulatory submissions. Good Clinical Practice 7:4.
de Cremiers F. ICH M4/the common technical document (CTD): comparison of clinical documents and summaries assessment practices in the United States, Europe and Japan. Drug Inf Jnl 1999; 33:601–614.s
Acknowledgment
The authors gratefully acknowledge the medical writers in pharmaceutical companies, CROs and consulting companies who took the time to respond to the questionnaire. They also thank Suzanne Wampler for her help with analyzing the data and Kathy Nomides for her help in developing the questionnaire.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Benamar, R., Hovde, M. The challenges of writing regulatory documents: a survey of medical writers. International Journal of Pharmaceutical Medicine 14, 265–269 (2000). https://doi.org/10.2165/00124363-200010000-00012
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2165/00124363-200010000-00012